Dietary fibre and ketone bodies: reduced urinary 3-hydroxybutyrate excretion in diabetics on guar Dietary fibre is known to modify carbohydrate absorption and metabolism in both normal and diabetic individuals.'-3 Except for reports on the action of certain forms of fibre in reducing serum cholesterol concentrations,3 however, no attention has been given to other changes in lipid metabolism.
Since urine testing for ketone bodies is still a major part of the clinical assessment of the diabetic, we have looked at the effect of guar gum on the output of 3-hydroxybutyric acid (3-OHB) in diabetic volunteers. If both 3-OHB and glucose outputs were reduced at the same time then this would suggest a general improvement in diabetic control rather than carbohydrate malabsorption.
Patients, methods, and results
Nine diabetics (4 men, 5 women aged 42± (SE of mean) 5 years) were studied. Their blood and urinary glucose data have been reported2; two were taking oral hypoglycaemic agents and seven insulin 36 ± 6 U/day.
Their mean weight was 106+ 5 % of desirable weight.
Seven patients were studied in hospital on metabolically controlled diets: identical two-day rotating menus were provided over both consecutive test and control five-day periods (the order being randomised and separated in five studies by a weekend). Two were studied as outpatients and kept the same meal plans throughout. During the control period patients took between 14 and 26 slices of crispbread per day with meals, and during the test period they took guar crispbread of the same composition except that it also contained 1 g guar/slice. Serum was obtained on the last day of each period and complete 24-hour urine collections were made throughout for analysis of creatinine (Technicon, SMA 12/60).4 Urinary 3-OHB, the ketone body least likely to be affected by storage, was estimated by an enzymatic technique modified for use with the Guildford 3500 enzyme analyser.5 The significance of differences was calculated using Student's t test for paired data.
The mean 3-OHB and glucose outputs over the last two days on guar were much lower than during the control period (see 1630 mg/24 h)), the large absolute differences in 3-OHB output between the mean values for test and control days were not significant. Mean 24-hour creatinine outputs over the two periods ranged from 10-7 to 12-6 mmol/24 h (1-2-1-4 g/24 h) and showed no trend, while the mean creatinine clearance on the last day of each period was identical (95 ± (SE of mean) 11 ml/min for the control period and 95 12 ml/min for the test period). The differences in 3-OHB excretion were therefore unlikely to have been due to incomplete urine collections or changes in renal function.
Comment
Although the percentage changes in urinary glucose and 3-OHB loss were of the same magnitude, a significant correlation was not seen. Nevertheless, the lower 3-OHB output may indicate a reduction in fat metabolism and contribute to the reduced insulin requirement seen in diabetics on high-fibre diets.1 2
The effect of guar on 3-OHB excretion further emphasises that its effect in reducing glucose loss is likely to be due to improved diabetic control rather than secondary to malabsorption of food and therefore reduced caloric intake. If this were not so, increased ketone-body excretion would be expected on a metabolic diet.
We conclude therefore that the observed reduction in 3-OHB excretion adds valuable independent support to the idea that certain types of dietary fibre may be useful in the treatment of diabetics. Taste loss associated with oral captopril treatment Captopril (SQ 14225) is an orally active converting enzyme inhibitor which is an effective antihypertensive agent in man.' A study has recently been completed in our unit2 comparing the antihypertensive properties of captopril with those of hydrochlorothiazide and examining the value of combining captopril with a diuretic in the management of moderate hypertension. During this study three out of 16 patients treated with captopril developed a definite disturbance of taste.
Case reports
Case 1-A 55-year-old woman was treated with captopril in doses increased at weekly intervals from 75 to 150, 300, and 450 mg/day. During the fifth week hydrochlorothiazide was also prescribed. At this time she complained that sweet foods tasted salty and that she had a persistently bitter taste in the mouth. After this she progressively lost taste discrimination. On testing she could recognise salt applied directly to the tongue and distinguish it from sugar, but after 20 seconds the sugar tasted bitter. Biochemical and haematological values were normal. Captopril (450 mg/day) and hydrochlorothiazide were continued for the next eight weeks but the disturbance of taste persisted. The captopril was replaced by methyldopa and two weeks later her taste had returned to normal.
Case 2-A 65-year-old man complained of tastge loss during his third week of captopril treatment. The dose at the time was 150 mg/day. No other drugs were prescribed. He also complained of a persistent salty taste in his mouth. Captopril was stopped and his taste recovered after about 10 days. The drug was then restarted at the same dose and five days later the disturbance of taste recurred. Biochemical and haematological values
